CN107319242A - L-cn effervescent tablet for slimming and preparation method thereof - Google Patents
L-cn effervescent tablet for slimming and preparation method thereof Download PDFInfo
- Publication number
- CN107319242A CN107319242A CN201710594349.6A CN201710594349A CN107319242A CN 107319242 A CN107319242 A CN 107319242A CN 201710594349 A CN201710594349 A CN 201710594349A CN 107319242 A CN107319242 A CN 107319242A
- Authority
- CN
- China
- Prior art keywords
- parts
- effervescent tablet
- slimming
- optional
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007938 effervescent tablet Substances 0.000 title claims abstract description 71
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 74
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 36
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 36
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 36
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims abstract description 36
- 241000748223 Alisma Species 0.000 claims abstract description 33
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 30
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract description 30
- 235000003599 food sweetener Nutrition 0.000 claims abstract description 29
- 239000003765 sweetening agent Substances 0.000 claims abstract description 29
- 239000002994 raw material Substances 0.000 claims abstract description 24
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 58
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 57
- 239000008187 granular material Substances 0.000 claims description 37
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 28
- 229930003427 Vitamin E Natural products 0.000 claims description 28
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 28
- 235000019165 vitamin E Nutrition 0.000 claims description 28
- 239000011709 vitamin E Substances 0.000 claims description 28
- 229940046009 vitamin E Drugs 0.000 claims description 28
- 235000020717 hawthorn extract Nutrition 0.000 claims description 26
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 23
- 235000013824 polyphenols Nutrition 0.000 claims description 23
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 18
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 18
- 235000011090 malic acid Nutrition 0.000 claims description 18
- 239000001630 malic acid Substances 0.000 claims description 18
- 239000004376 Sucralose Substances 0.000 claims description 15
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical group O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 15
- 235000019408 sucralose Nutrition 0.000 claims description 15
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 14
- 238000005550 wet granulation Methods 0.000 claims description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 6
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 claims description 3
- 229910000020 calcium bicarbonate Inorganic materials 0.000 claims description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000001530 fumaric acid Substances 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 3
- 239000011975 tartaric acid Substances 0.000 claims description 3
- 235000002906 tartaric acid Nutrition 0.000 claims description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 2
- 239000001509 sodium citrate Substances 0.000 claims description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 2
- RZALONVQKUWRRY-FYZOBXCZSA-N 2,3-dihydroxybutanedioic acid;(3r)-3-hydroxy-4-(trimethylazaniumyl)butanoate Chemical compound OC(=O)C(O)C(O)C(O)=O.C[N+](C)(C)C[C@H](O)CC([O-])=O RZALONVQKUWRRY-FYZOBXCZSA-N 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- WJEIYVAPNMUNIU-UHFFFAOYSA-N [Na].OC(O)=O Chemical group [Na].OC(O)=O WJEIYVAPNMUNIU-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical group 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 26
- 239000003814 drug Substances 0.000 abstract description 11
- 238000000034 method Methods 0.000 abstract description 8
- 238000010521 absorption reaction Methods 0.000 abstract description 7
- 238000000354 decomposition reaction Methods 0.000 abstract description 7
- 238000005516 engineering process Methods 0.000 abstract description 6
- 206010067484 Adverse reaction Diseases 0.000 abstract description 4
- 230000006838 adverse reaction Effects 0.000 abstract description 4
- 230000036541 health Effects 0.000 abstract description 2
- 230000002045 lasting effect Effects 0.000 abstract 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 21
- 235000015165 citric acid Nutrition 0.000 description 17
- 239000003925 fat Substances 0.000 description 14
- 230000000670 limiting effect Effects 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 11
- 230000037396 body weight Effects 0.000 description 9
- 238000001514 detection method Methods 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 150000001720 carbohydrates Chemical class 0.000 description 7
- 235000014633 carbohydrates Nutrition 0.000 description 7
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 210000000577 adipose tissue Anatomy 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 235000020985 whole grains Nutrition 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 210000000852 deltoid muscle Anatomy 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 241000186000 Bifidobacterium Species 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- 244000302512 Momordica charantia Species 0.000 description 3
- 235000009811 Momordica charantia Nutrition 0.000 description 3
- 235000009812 Momordica cochinchinensis Nutrition 0.000 description 3
- 235000018365 Momordica dioica Nutrition 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241001092040 Crataegus Species 0.000 description 2
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 2
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 2
- 235000009685 Crataegus X maligna Nutrition 0.000 description 2
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 2
- 235000009486 Crataegus bullatus Nutrition 0.000 description 2
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 2
- 235000009682 Crataegus limnophila Nutrition 0.000 description 2
- 235000004423 Crataegus monogyna Nutrition 0.000 description 2
- 235000002313 Crataegus paludosa Nutrition 0.000 description 2
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- YXVXMURDCBMPRH-UHFFFAOYSA-N Lirinidine Natural products C1C2=CC=CC=C2C2=C(O)C(OC)=CC3=C2C1N(C)CC3 YXVXMURDCBMPRH-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- ORJVQPIHKOARKV-UHFFFAOYSA-N Nuciferine Natural products C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2C1N(C)CC3 ORJVQPIHKOARKV-UHFFFAOYSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 230000035508 accumulation Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002213 flavones Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 235000011087 fumaric acid Nutrition 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- ORJVQPIHKOARKV-OAHLLOKOSA-N nuciferine Chemical compound C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2[C@@H]1N(C)CC3 ORJVQPIHKOARKV-OAHLLOKOSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000004080 punching Methods 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000019605 sweet taste sensations Nutrition 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- -1 triterpene acetol derivatives Chemical class 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- GADIJPCDIWZEMB-BTNVMJJCSA-N (2r,3r)-2,3-dihydroxybutanedioate;hydron;(3r)-3-hydroxy-4-(trimethylazaniumyl)butanoate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C[N+](C)(C)C[C@H](O)CC([O-])=O.C[N+](C)(C)C[C@H](O)CC([O-])=O GADIJPCDIWZEMB-BTNVMJJCSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000036523 atherogenesis Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000021074 carbohydrate intake Nutrition 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 231100000405 induce cancer Toxicity 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 125000002640 tocopherol group Chemical group 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- 150000004823 xylans Chemical class 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
- A23L2/40—Effervescence-generating compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention provides a kind of l-cn effervescent tablet for slimming and preparation method thereof, it is related to health product technology field, is mainly prepared from by the following raw material according to the mass fraction：400 500 parts of L-carnitine-L-tartrate, 60 70 parts of Lotus Leafextract, 130 140 parts of Alisma extract, 65 75 parts of leucine, 225 245 parts of xylo-oligosaccharide, sour 500 600 parts of agent, 200 300 parts of alkaline agent, 14 parts of sweetener, it is mostly Western medicine to alleviate the existing medicine of fat-reducing on the market, intrinsic adverse reaction and adjoint side effect are larger, the technical problem that slimmer can be influenceed healthy, decomposition fatty in body can not only be accelerated and be converted into energy by having reached, suppress absorption of the body to fat and sugar class, the purpose for reaching natural contral and losing weight, and effect is lasting, it is without any side effects to human body, it will not rebound, the healthy technique effect of slimmer can be effectively facilitated.
Description
Technical field
The present invention relates to health product technology field, more particularly, to a kind of l-cn effervescent tablet for slimming and its preparation side
Method.
Background technology
Worldwide, fat number is raised with surprising rapidity, obesity have become with AIDS, take drugs and
The excessive drinking great society problem of the world four arranged side by side, medical field is also the coronary heart disease relevant with obesity, hypertension, hyperlipidemia, glycosuria
Disease, cerebrovas-cularaccident are referred to as " dead quintet ".The preventing and treating of science and improvement obesity symptom have become common in world wide
The social concern of concern.
The fat not only figure of influence people, image and daily routines, can also threaten healthy, induce cancer, gall-bladder
30 multiple complications such as scorching and respiratory system.Common fat-reducing medicine is Western medicine currently on the market, and although Western medicine has quick aobvious
The effect of fat-reducing is write, but the intrinsic adverse reaction of chemicals and adjoint side effect are larger, slimmer can be influenceed healthy.
In view of this, it is special to propose the present invention.
The content of the invention
An object of the present invention is that providing a kind of l-cn fat-reducing rises piece, to alleviate existing medicine of losing weight on the market
It is Western medicine, although have quick significant fat-reducing effect, but the intrinsic adverse reaction of chemicals and adjoint side effect are larger, meeting
The technical problem for influenceing slimmer healthy.
The l-cn effervescent tablet for slimming that the present invention is provided, is mainly prepared from by the following raw material according to the mass fraction：
400-500 parts of L-carnitine-L-tartrate, 60-70 parts of Lotus Leafextract, 130-140 parts of Alisma extract, leucine 65-75
Part, 225-245 parts of xylo-oligosaccharide, sour agent 500-600 parts, 200-300 parts of alkaline agent, 1-4 parts of sweetener.
Further, the l-cn effervescent tablet for slimming, is mainly prepared from by the following raw material according to the mass fraction：
460-470 parts of L-carnitine-L-tartrate, 65-70 parts of Lotus Leafextract, 132-136 parts of Alisma extract, leucine 68-72
Part, 230-240 parts of xylo-oligosaccharide, sour agent 500-600 parts, 200-300 parts of alkaline agent, 2-3 parts of sweetener.
Further, the l-cn effervescent tablet for slimming also includes the following raw material according to the mass fraction：Tea Polyphenols 15-
25 parts, 15-25 parts of Bitter Melon P.E, 3-7 parts of vitamin E, 10-20 parts of haw thorn extract.
Further, the sour agent in tartaric acid, malic acid, fumaric acid, citric acid or sodium citrate at least one
Kind；It is preferred that, the sour agent is the mixture of malic acid and citric acid, and both mass ratioes are 1：(3-4).
Further, the alkaline agent is selected from potassium carbonate, sodium carbonate, calcium carbonate, saleratus, sodium acid carbonate and calcium bicarbonate
At least one of；It is preferred that, the alkaline agent is sodium carbonate.
Further, the sweetener is selected from least one of Sucralose, lactose and xylitol；It is preferred that, it is described
Sweetener is Sucralose.
The second object of the present invention is the provision of the preparation method of above-mentioned l-cn effervescent tablet for slimming, existing to alleviate
Fat-reducing medicine is Western medicine on the market, although have a quick significant fat-reducing effect, but the intrinsic adverse reaction of chemicals and adjoint
Side effect it is larger, the technical problem that slimmer can be influenceed healthy.
The preparation method for the l-cn effervescent tablet for slimming that the present invention is provided, comprises the following steps：
(a) by Lotus Leafextract, L-carnitine-L-tartrate, sour agent, optional Tea Polyphenols, optional Bitter Melon P.E,
Optional haw thorn extract and optional vitamin E mixing, are made the first granule；
(b) Alisma extract, xylo-oligosaccharide, alkaline agent and sweetener are well mixed, the second granule is made；
(c) the first granule, the second granule and leucine are well mixed, carry out tabletting, that is, l-cn is made and subtracts
Fertile effervescent tablet.
Further, the preparation method of above-mentioned l-cn effervescent tablet for slimming also includes step (s), and the step (s) sets
It is placed in before the step (a), the step (s) is by Lotus Leafextract, L-carnitine-L-tartrate, Alisma extract, low
Xylan, sour agent, alkaline agent, sweetener, optional Bitter Melon P.E, optional Tea Polyphenols, optional vitamin E, optional mountain
Short, bristly hair or beard extract is respectively crushed, and crosses 80 mesh sieves.
Further, first granule and second granule are formed by drying after wet granulation.
Further, the granularity of first granule and second granule is 14-18 mesh, preferably 16 mesh.
The l-cn effervescent tablet for slimming that the present invention is provided, is carried by L-carnitine-L-tartrate, Lotus Leafextract, rhizoma alismatis
Thing, leucine, xylo-oligosaccharide, sour agent, alkaline agent and sweetener coordinated are taken, decomposition fatty in body and conversion is can speed up
For energy, while suppressing absorption of the body to fat and sugar class, the intake of Exogenous fatty and carbohydrate is reduced, so as to reach nature control
The purpose made and lost weight.In addition, the effervescent tablet effect that the present invention is provided is persistently, it is without any side effects to human body, and not
It can rebound, the healthy of slimmer can be effectively facilitated.
The preparation method for the l-cn effervescent tablet for slimming that the present invention is provided, technique is simple, easy to operate, it is easy to carry out big
Industrial production, reduction prepares cost, improves preparation efficiency.
Embodiment
Embodiment of the present invention is described in detail below in conjunction with embodiment, but those skilled in the art will
Understand, the following example is merely to illustrate the present invention, and is not construed as limiting the scope of the present invention.It is unreceipted specific in embodiment
Condition person, the condition advised according to normal condition or manufacturer is carried out.Agents useful for same or the unreceipted production firm person of instrument, be
The conventional products that can be obtained by commercially available purchase.
According to an aspect of the present invention, the invention provides a kind of l-cn effervescent tablet for slimming, mainly by by quality
The following raw material of number meter is prepared from：400-500 parts of L-carnitine-L-tartrate, 60-70 parts of Lotus Leafextract, rhizoma alismatis is extracted
130-140 parts of thing, 65-75 parts of leucine, 225-245 parts of xylo-oligosaccharide, sour agent 500-600 parts, 200-300 parts of alkaline agent, sweet taste
1-4 parts of agent.
The l-cn effervescent tablet for slimming that the present invention is provided, the l-cn effervescent tablet for slimming that the present invention is provided, passes through a left side
Rotation carnitine tartrate, Lotus Leafextract, Alisma extract, leucine, xylo-oligosaccharide, sour agent, alkaline agent and sweetener collaboration are matched somebody with somebody
Close, can speed up decomposition fatty in body and be converted into energy, while suppressing absorption of the body to fat and sugar class, reduce outer
The intake of source fat and sugar class, so that the purpose for reaching natural contral and losing weight.In addition, the effervescent tablet effect that the present invention is provided
Fruit is persistently, without any side effects to human body, and will not rebound, and can effectively facilitate the healthy of slimmer.
In the present invention, the typical but non-limiting mass fraction of L-carnitine-L-tartrate as 405,410,415,
420th, 425,430,435,440,445,450,455,460,465,470,475,480,485,490 or 495 parts.
L-carnitine-L-tartrate is the stable form of l-cn, and it is difficult the moisture absorption, is easily protected under humid conditions
It is fixed to keep steady.
L-cn is a kind of amino acid for promoting adipose conversion for energy；Main Physiological Function function is to promote fat
Energy is changed into, moisture and muscle can not be reduced while reducing body fat, losing weight by taking l-cn.
In the present invention, the typical but non-limiting mass fraction of Lotus Leafextract as 60.5,61,61.5,62,
62.5th, 63,63.5,64,64.5,65,65.5,66,66.5,67,67.5,68,68.5,69 or 69.5.
Lotus leaf contains nuciferine, miltanthin, a variety of alkaloids such as Nuciferine and flavones and vitamin C, is that China is traditional
Cleaning blood and reducing fat good medicine and fat-reducing treasure, have relieve inflammation or internal heat, diuresis, fat eliminating, the effect of defaecation.
The typical but non-limiting mass fraction of Alisma extract as 130.5,131,131.5,132,132.5,
133rd, 133.5,134,134.5,135,135.5,136,136.5137,137.5,138,138.5,139 or 139.5.
Alisma extract contains a variety of tetracyclic triterpene acetol derivatives, and lecithin, choline, alditol etc., and theory of traditional Chinese medical science is recognized
It is cold in nature for its, there is clearing damp and promoting diuresis, modern hospital is studied, and rhizoma alismatis can reduce serum total cholesterol and triacylglycerol contains
Amount, slows down atherogenesis.
The typical but non-limiting mass fraction of leucine as 65.5,66,66.5,67,67.5,68,68.5,69,
69.5th, 70,70.5,71,71.5,72,72.5,73,73.5,74 or 74.5.
Leucine is a kind of maximally effective branched-chain amino acid, can effectively prevent muscle loss, controls blood glucose, and to body
Tissue provides energy.
The typical but non-limiting mass fraction of xylo-oligosaccharide as 225.5,226,226.5,227,227.5,228,
228.5th, 229,229.5,230,230.5,231,231.5,232,232.5,233,233.5,234 or 234.5.
Xylo-oligosaccharide is also known as wood oligose, is that the feature being combined into by 2-7 xylose molecule with β-Isosorbide-5-Nitrae glycosidic bond polymerize
Sugar, is to polymerize one of most strong kind of propagation Bifidobacterium function in carbohydrate, the both effectiveness of it is nearly the 20 of other polymerization carbohydrates
Times, there is no the enzyme for hydrolyzing xylo-oligosaccharide in human body intestinal canal, so it is preferably that Bifidobacterium is utilized that it, which can be directly entered big enteral,
Promote Bifidobacterium propagation to produce a variety of organic acids simultaneously, reduce enteron aisle pH value, suppress harmful bacteria growing, make probiotics in enteron aisle
A large amount of propagation, reach health-care efficacy.
The typical but non-limiting mass fraction of sour agent as 505,510,515,520,525,530,535,540,
545th, 550,555,560,565,570,575,580,585,590 or 595.
In a preferred embodiment of the invention, sour agent is selected from tartaric acid, malic acid, fumaric acid, citric acid or citric acid
At least one of sodium, it is preferred that sour agent is the mixture of malic acid and citric acid, and both mass ratioes are 1：(5-6).
When the mixture that sour agent is malic acid and citric acid, and both mass ratioes are 1：(5-6), obtained left-handed meat
The speed of alkali effervescent tablet for slimming disintegration faster, also more clarify by the solution after dissolving.
The typical but non-limiting mass fraction of alkaline agent as 205,210,215,220,225,230,235,240,
245th, 250,255,260,265,270,275,280,285,290 or 295.
In a preferred embodiment of the invention, alkaline agent is selected from potassium carbonate, sodium carbonate, calcium carbonate, saleratus, bicarbonate
At least one of sodium and calcium bicarbonate, it is preferred that the alkaline agent is sodium acid carbonate.
When alkaline agent be sodium acid carbonate when, the l-cn effervescent tablet for slimming disintegration rate obtained by it faster, after dissolving
Solution is also more clarified.
The typical but non-limiting mass fraction of sweetener as 1.1,1.2,1.3,1.4,1.5,1.6,1.7,1.8,
1.9th, 2,2.1,2.2,2.3,2.4,2.5,2.6,2.7,2.8,2.9,3,3.1,3.2,3.3,3.4,3.5,3.6,3.7,3.8 or
3.9。
In a preferred embodiment of the invention, sweetener is selected from least one of Sucralose, lactose and xylitol；
It is preferred that, the sweetener is Sucralose.
When sweetener is Sucralose, the mouthfeel of prepared l-cn effervescent tablet for slimming is more preferable, more by slimmer
Welcome.
In a preferred embodiment of the invention, l-cn carnitine effervescent tablet for slimming also include according to the mass fraction as
Lower raw material：15-25 parts of Tea Polyphenols, 15-25 parts of Bitter Melon P.E, 20-30 parts of vitamin E, 10-20 parts of haw thorn extract.
In a preferred embodiment of the invention, the typical but non-limiting mass fraction of Tea Polyphenols as 15.5,16,
16.5th, 17,17.5,18,18.5,19,19.5,20,20.5,21,21.5,22,22.5,23,23.5,24 or 24.5.
Tea Polyphenols is the general name of Polyphenols of Tea, in addition to oxidation, also with bacteriostasis, such as to Portugal
Grape coccus, Escherichia coli, hay bacillus etc. have inhibitory action, while also having the work of the formation and the accumulation that suppress nitrite
With.
In a preferred embodiment of the invention, the typical but non-limiting mass fraction of Bitter Melon P.E is such as
15.5th, 16,16.5,17,17.5,18,18.5,19,19.5,20,20.5,21,21.5,22,22.5,23,23.5,24 or
24.5。
Protein component and a large amount of vitamins in balsam pear can improve body's immunity, immunocyte is had killing
The effect of cancer cell, while can also effectively suppress the canceration of normal cell and promote the special recovery for becoming cell.In addition, balsam pear is also
It is anti-oxidant to wait effect with reducing blood lipid and blood pressure, and the conveying of prevention sclerotin, regulation endocrine, while improving anti-inside body
Answer mechanism.
In a preferred embodiment of the invention, the typical but non-limiting mass fraction of vitamin E as 3.2,
3.4th, 3.6,3.8,4,4.2,4.4,4.6,4.8,5,5.2,5.4,5.6,5.8,6,6.2,6.4,6.6 or 6.8.
Vitamin E is a kind of liposoluble vitamin, and its hydrolysate is tocopherol, is one of topmost antioxidant,
Tocopherol can promote sex hormone to secrete, and increase women estrogen concentrations, improve fecundity, suppress the mistake in ocular lens body
Oxide ester reacts, and makes peripheral vasodilation, improves blood circulation.Vitamin E is in prevention cardiovascular and cerebrovascular disease, tumour, diabetes
And there is wide application in terms of other complication, central nervous system disease, motor system disease, disease of skin.
In a preferred embodiment of the invention, the typical but non-limiting mass fraction of haw thorn extract is such as
10.5th, 11,11.5,12,12.5,13,13.5,14,14.5,15,15.5,16,16.5,17,17.5,18,18.5,19 or
19.5。
Hawthorn contains flavones, citric acid, malic acid, ascorbic acid and carbohydrate, has hypotensive, promotes stomach and intestine row's fat
Effect.The traditional Chinese medical science thinks, hawthorn can invigorating the spleen disperse accumulations, it is favourable to losing weight, auxiliary can control obesity.
In a preferred embodiment of the invention, by adding Tea Polyphenols, Bitter Melon P.E, vitamin in primary raw material
E and haw thorn extract, are allowed to compatible with L-TARTARIC ACID salt, Lotus Leafextract, Alisma extract, leucine and xylo-oligosaccharide,
Decomposition and conversion fatty in body can be further speeded up, while the intake of Exogenous fatty and carbohydrate is further reduced, not
Diarrhoea, not apocleisis, it is not weak in the case of, reach faster and better fat-reducing effect.
According to another aspect of the present invention, present invention also offers the preparation side of above-mentioned l-cn effervescent tablet for slimming
Method, comprises the following steps：
(a) by Lotus Leafextract, L-carnitine-L-tartrate, sour agent, optional Tea Polyphenols, optional Bitter Melon P.E,
Optional haw thorn extract and optional vitamin E mixing, are made the first granule；
(b) Alisma extract, xylo-oligosaccharide, alkaline agent and sweetener are well mixed, the second granule is made；
(c) the first granule, the second granule and leucine are well mixed, carry out tabletting, that is, l-cn is made and subtracts
Fertile effervescent tablet.
The preparation method for the l-cn effervescent tablet for slimming that the present invention is provided, technique is simple, easy to operate, it is easy to carry out big
Industrial production, reduction prepares cost, improves preparation efficiency.
In a preferred embodiment of the invention, the preparation method of l-cn effervescent tablet for slimming also comprises the following steps
(s), the step (s) is arranged at before the step (a) and step (b), the step (s) be arranged at the step (a) it
Before, the step (s) be by Lotus Leafextract, L-carnitine-L-tartrate, Alisma extract, xylo-oligosaccharide, sour agent, alkaline agent,
Sweetener, optional Bitter Melon P.E, optional Tea Polyphenols, optional vitamin E, optional haw thorn extract are respectively carried out
Crush.
By by Lotus Leafextract, L-carnitine-L-tartrate, Alisma extract, xylo-oligosaccharide, sour agent, alkaline agent, sweet taste
Agent, optional Bitter Melon P.E, optional vitamin E, optional haw thorn extract are crushed, and cross 80 mesh sieves so that lotus
Leaf extract, L-carnitine-L-tartrate, Alisma extract, xylo-oligosaccharide, sour agent, alkaline agent, sweetener, optional balsam pear are extracted
Thing, optional vitamin E, optional haw thorn extract particle diameter it is smaller, when carrying out married operation, mix between many raw materials
It is more uniform, to reduce the drug effect difference between the different tablets of obtained l-cn effervescent tablet for slimming.
In a preferred embodiment of the invention, the first granule and the second granule are by dry after wet granulation
Into.
In a preferred embodiment of the invention, in step (a), the material mixed is poured into wet granulator
Row wet granulation, the wet granular made is crossed after 16 mesh sieves, is dried at 55-70 DEG C, carries out whole grain after drying again, and cross 16
Mesh sieve, that is, be made the first granule.
In step (b), the preparation technology of the second granule will not be repeated here with the preparation technology of the first granule.
In a preferred embodiment of the invention, leucine also passes through crushing before combination, and crosses 100 mesh sieves, Ran Houzai
Mixed pressuring plate is carried out with the first granule and the second granule.
In a preferred embodiment of the invention, the granularity of the first granule and the second granule is 14-18 mesh, preferably
For 16 mesh.
By by the Task-size Controlling of the first granule and the second granule in 14-18 mesh, in order to carry out follow-up pressure
During blade technolgy, more uniform, the progress for tablet forming technique of being also more convenient for of mixing.
In a preferred embodiment of the invention, the preparation method of l-cn effervescent tablet for slimming, enters in accordance with the following steps
OK：
(s) Lotus Leafextract, L-carnitine-L-tartrate, Alisma extract, xylo-oligosaccharide, sour agent, alkaline agent, sweetener,
Optional Bitter Melon P.E, optional vitamin E, optional haw thorn extract are respectively crushed, and cross 80 mesh sieves；
(a) by Lotus Leafextract, L-carnitine-L-tartrate, sour agent, optional Tea Polyphenols, optional Bitter Melon P.E,
Optional haw thorn extract and optional vitamin E mixing, add ethanol, carry out wet granulation, and cross 16 mesh sieves, obtain first
Wet granular agent, by the first wet granular agent at 65 DEG C, is dried, and whole grain crosses 16 mesh sieves, obtains the first granule；
(b) Alisma extract, xylo-oligosaccharide, alkaline agent and sweetener are well mixed, add ethanol, carry out wet granulation,
And 16 mesh sieves are crossed, the second wet granular agent is obtained, by the second wet granular agent at 65 DEG C, is dried, and whole grain crosses 16 mesh sieves, obtains
Second granule；
(c) leucine is crushed, and is mixed after 100 mesh sieves excessively with the first granule and the second granule and carry out tabletting,
L-cn effervescent tablet for slimming is made.
For the ease of understanding the technical scheme of the invention provided, the technical scheme provided with reference to embodiment the present invention
It is further described.
Embodiment 1
A kind of l-cn effervescent tablet for slimming is present embodiments provided, is prepared from by the raw material of following mass fraction meter：
400 parts of L-carnitine-L-tartrate, 60 parts of Lotus Leafextract, 140 parts of Alisma extract, 65 parts of leucine, xylo-oligosaccharide 245
Part, 450 parts of citric acid, 150 parts of malic acid, 297 parts of sodium carbonate, 1 part of Sucralose.
Embodiment 2
A kind of l-cn effervescent tablet for slimming is present embodiments provided, is prepared from by the raw material of following mass fraction meter：
496 parts of L-carnitine-L-tartrate, 70 parts of Lotus Leafextract, 130 parts of Alisma extract, 75 parts of leucine, xylo-oligosaccharide 225
Part, 425 parts of citric acid, 125 parts of malic acid, 250 parts of sodium carbonate, 4 parts of Sucralose.
Embodiment 3
A kind of l-cn effervescent tablet for slimming is present embodiments provided, is prepared from by the raw material of following mass fraction meter：
460 parts of L-carnitine-L-tartrate, 70 parts of Lotus Leafextract, 132 parts of Alisma extract, 72 parts of leucine, xylo-oligosaccharide 230
Part, 445 parts of citric acid, 145 parts of malic acid, 244 parts of sodium carbonate, 2 parts of Sucralose.
Embodiment 4
A kind of l-cn effervescent tablet for slimming is present embodiments provided, is prepared from by the raw material of following mass fraction meter：
467 parts of L-carnitine-L-tartrate, 67 parts of Lotus Leafextract, 134 parts of Alisma extract, 70 parts of leucine, xylo-oligosaccharide 234
Part, 439.5 parts of citric acid, 134 parts of malic acid, 252 parts of sodium carbonate, 2.5 parts of Sucralose.
Embodiment 5
A kind of l-cn effervescent tablet for slimming is present embodiments provided, is prepared from by the raw material of following mass fraction meter：
460 parts of L-carnitine-L-tartrate, 65 parts of Lotus Leafextract, 130 parts of Alisma extract, 70 parts of leucine, xylo-oligosaccharide 230
Part, 15 parts of Tea Polyphenols, 25 parts of Bitter Melon P.E, 3 parts of vitamin E, 20 parts of haw thorn extract, 429 parts of citric acid, malic acid 130
Part, 220 parts of sodium carbonate, 3 parts of Sucralose.
Embodiment 6
A kind of l-cn effervescent tablet for slimming is present embodiments provided, is prepared from by the raw material of following mass fraction meter：
470 parts of L-carnitine-L-tartrate, 68 parts of Lotus Leafextract, 132 parts of Alisma extract, 68 parts of leucine, xylo-oligosaccharide 232
Part, 25 parts of Tea Polyphenols, 15 parts of Bitter Melon P.E, 7 parts of vitamin E, 10 parts of haw thorn extract, 419 parts of citric acid, malic acid 121
Part, 230 parts of sodium carbonate, 3 parts of Sucralose.
Embodiment 7
A kind of l-cn effervescent tablet for slimming is present embodiments provided, is prepared from by the raw material of following mass fraction meter：
467 parts of L-carnitine-L-tartrate, 67 parts of Lotus Leafextract, 134 parts of Alisma extract, 70 parts of leucine, xylo-oligosaccharide 234
Part, 20 parts of Tea Polyphenols, 20 parts of Bitter Melon P.E, 5 parts of vitamin E, 15 parts of haw thorn extract, 410 parts of citric acid, malic acid 124
Part, 222 parts of sodium carbonate, 2 parts of Sucralose.
The preparation method for the l-cn effervescent tablet for slimming that embodiment 1-7 is provided, is carried out in accordance with the following steps：
(s) Lotus Leafextract, L-carnitine-L-tartrate, Alisma extract, xylo-oligosaccharide, sour agent, alkaline agent, sweetener,
Optional Bitter Melon P.E, optional vitamin E, optional haw thorn extract are respectively crushed, and cross 80 mesh sieves；
(a) by Lotus Leafextract, L-carnitine-L-tartrate, sour agent, optional Tea Polyphenols, optional Bitter Melon P.E,
Optional haw thorn extract and optional vitamin E mixing, add ethanol, carry out wet granulation, and cross 16 mesh sieves, obtain first
Wet granular agent, by the first wet granular agent at 65 DEG C, is dried, and whole grain crosses 16 mesh sieves, obtains the first granule；
(b) Alisma extract, xylo-oligosaccharide, alkaline agent and sweetener are well mixed, add ethanol, carry out wet granulation,
And 16 mesh sieves are crossed, the second wet granular agent is obtained, by the second wet granular agent at 65 DEG C, is dried, and whole grain crosses 16 mesh sieves, obtains
Second granule；
(c) leucine is crushed, and is mixed after 100 mesh sieves excessively with the first granule and the second granule and carry out tabletting,
L-cn effervescent tablet for slimming is made.
Comparative example 1
This comparative example provide a kind of l-cn effervescent tablet for slimming, by according to the mass fraction the following raw material prepare and
Into：600 parts of L-carnitine-L-tartrate, 20 parts of Lotus Leafextract, 40 parts of Alisma extract, 30 parts of leucine, xylo-oligosaccharide 282
Part, 439.5 parts of citric acid, 134 parts of malic acid, 252 parts of sodium carbonate, 2.5 parts of Sucralose.
Comparative example 2
This comparative example provide a kind of l-cn effervescent tablet for slimming, by according to the mass fraction the following raw material prepare and
Into：350 parts of L-carnitine-L-tartrate, 120 parts of Lotus Leafextract, 200 parts of Alisma extract, 120 parts of leucine, xylo-oligosaccharide
182 parts, 439.5 parts of citric acid, 134 parts of malic acid, 252 parts of sodium carbonate, 2.5 parts of Sucralose.
The preparation method be the same as Example 7 for the l-cn effervescent tablet for slimming that comparative example 1-2 is provided, will not be repeated here.
The l-cn effervescent tablet for slimming that above-described embodiment 1-7 and comparative example 1-2 is provided carries out the detection of correlated performance,
Testing result is as shown in the table：
The l-cn effervescent tablet for slimming performance detection table of table 1
It can be seen from Table 1 that, the l-cn effervescent tablet for slimming piece shape that 1-7 of the embodiment of the present invention is provided is good, without glutinous punching,
Solution clear after dissolving, pH value is between 4.1-4.3, and disintegration is rapid, and disintegration time was 80-84s, in the time of 3 months
Interior weight and taste keep being basically unchanged, and stability is good.
By embodiment 1-7 and comparative example 1-2 contrast, when L-carnitine-L-tartrate, Lotus Leafextract, rhizoma alismatis
Extract, leucine, xylo-oligosaccharide, optional haw thorn extract, optional Tea Polyphenols, optional Bitter Melon P.E and and optionally
Vitamin E, citric acid, malic acid and sodium carbonate in the range of specific mass fraction when, each raw material coordinated is obtained
L-cn effervescent tablet for slimming piece shape it is good, without glutinous punching, solution clear, allows drinking person more to trust after dissolving.
In addition, the l-cn effervescent tablet for slimming that embodiment 1-7 and comparative example 1-2 are provided is in January, 2 months and March point
Microbioassay has not been carried out, does not find the presence of microorganism.
The l-cn effervescent tablet for slimming that above-described embodiment 1-7 and comparative example 1-2 is provided is according to the Ministry of Public Health《Health food
Examine and assessment technique standard》Defined weight losing function human experiment method carries out interventional population investigation, by the body weight of subject,
500 subjects are randomly divided into 10 groups by body fat weight, every group of 50 people, respectively A-J groups, wherein, A-G group test-meal embodiments 1-
The 5 l-cn effervescent tablet for slimming provided, the l-cn effervescent tablet for slimming that H-I group test-meal comparative examples 1-2 is provided, J groups
For blank control group, A-J groups take (every 180mg) according to the dosage that twice daily, 1 tablet once, and J groups take placebo,
Continuous 45 days, do not change original eating habit during experiment, normal diet, experimental period terminates, carry out related performance indicators survey
It is fixed, it is as a result as follows：
1st, blood pressure, heart rate, urine, feces, blood routine and biochemical indicator detection before and after test-meal
Detection discovery is carried out to the blood pressure of 10 groups of subjects, heart rate, urine, feces, blood routine and biochemical indicator before and after test-meal,
The red blood cell of 10 groups of subjects, leucocyte, hemoglobin, blood platelet, total serum protein, albumin, glutamic-pyruvic transaminase, millet straw turn
Ammonia enzyme, creatinine, urea nitrogen, blood pressure and heart rate do not occur significant changes, routine urinalysis and just conventional also without change, and this illustrates this hair
The l-cn effervescent tablet for slimming that bright embodiment 1-7 and comparative example 1-2 are provided does not have toxic side effect to human body, does not interfere with edible
Person's is healthy.
2nd, maximal oxygen uptake and the detection of main nutrients intake before and after test-meal
Maximal oxygen uptake and main nutrients to 10 groups of subjects before and after test-meal are measured, as a result such as table 2 and the institute of table 3
Show：
Maximal oxygen uptake and main nutrients intake detection table before and after the test-meal of table 2
Protein and carbohydrate intake detection table before and after the test-meal of table 3
From table 2 and table 3 as can be seen that the maximal oxygen uptake and main nutrients intake of subject have no bright before and after experiment
Aobvious change.
3rd, body weight, body fat total amount and fat percentage are determined before and after test-meal
Result is measured to the body weight and body fat total amount of 10 groups of subjects before and after test-meal as shown in table 4：
Body weight and body fat total amount detection tables of data before and after the test-meal of table 4
The contrast of A-G groups and J groups can be seen that the l-cn fat-reducing that subject takes embodiment 1-7 offers from table 4
Effervescent tablet 45 days, more than weight loss 1.34kg, and the body weight for taking the subject of placebo does not have significant change, this explanation is real
The body weight of subject can effectively be mitigated by applying a l-cn effervescent tablet for slimming for 1-7 offers, reduced body ester total amount, reached fat-reducing
Effect.
In addition, by the contrast of A-G groups and H-I groups as can be seen that the l-cn fat-reducing effervesce that embodiment 1-7 is provided
Piece by L-carnitine-L-tartrate, Lotus Leafextract, Alisma extract, leucine, xylo-oligosaccharide, optional Tea Polyphenols, appoint
The haw thorn extract of choosing, optional vitamin E, optional Bitter Melon P.E, sour agent, alkaline agent and sweetener coordinated, can
Accelerate decomposition fatty in body and be converted into energy, while suppressing absorption of the body to fat and sugar class, reduce Exogenous fatty
With the intake of carbohydrate so that the purpose for reaching natural contral and losing weight.
By the contrast of E-G groups and A-D groups as can be seen that many when adding tea in the raw material of l-cn effervescent tablet for slimming
After phenol, haw thorn extract, Bitter Melon P.E and vitamin E, it is lost weight, and body weight and body ester the total amount reduction of its subject is more
It hurry up, fat-reducing effect is more preferable.
4th, subcutaneous fat thickness measuring
Subcutaneous fat under the deltoid muscle and omoplate of 10 groups of subjects before and after test-meal is measured.As a result it is as shown in table 5：
Subcutaneous fat thickness detects table under the test-meal front-rear triangular flesh of table 5 and omoplate
It is measured to 3cm by the navel of 10 groups of subjects before and after test-meal and with the subcutaneous fat of anterior superior spine, as a result such as table 6
It is shown：
Navel side 3cm and the subcutaneous fat measurement data table with anterior superior spine before and after the test-meal of table 6
The contrast of A-G groups and J groups can be seen that the left-handed meat that subject takes embodiment 1-7 offers from table 5 and table 6
Alkali effervescent tablet for slimming 45 days, deltoid muscle subcutaneous fat reduces subcutaneous fat thickness under more than 1mm, omoplate and reduces more than 0.93mm,
3cm subcutaneous fats reduce more than 0.4mm by navel, and anterior superior spine subcutaneous fat reduces more than 0.4mm, and takes the tested of placebo
The body weight of person does not have significant change, and the l-cn effervescent tablet for slimming that this explanation embodiment 1-7 is provided can effectively reduce triangle
Subcutaneous fat, navel side 3cm subcutaneous fats and anterior superior spine subcutaneous fat are significantly reduced under flesh subcutaneous fat, omoplate, with aobvious
The fat-reducing effect of work.
In addition, by the contrast of A-G groups in table 5 and table 6 and H-I groups as can be seen that the left-handed meat that embodiment 1-7 is provided
Alkali effervescent tablet for slimming passes through L-carnitine-L-tartrate, Lotus Leafextract, Alisma extract, leucine, xylo-oligosaccharide, optional
Tea Polyphenols, optional haw thorn extract, optional vitamin E, optional Bitter Melon P.E, sour agent, alkaline agent and sweetener collaboration
Coordinate, can speed up decomposition fatty in body and be converted into energy, while suppressing absorption of the body to fat and sugar class, reduce
The intake of Exogenous fatty and carbohydrate, thus reach subcutaneous fat under deltoid muscle subcutaneous fat, omoplate, by navel 3cm subcutaneous fats and
The purpose that anterior superior spine subcutaneous fat is significantly reduced and lost weight.
By the contrast of E-G groups in table 5 and table 6 and A-D groups as can be seen that when in the raw material of l-cn effervescent tablet for slimming
Add after Tea Polyphenols, haw thorn extract, Bitter Melon P.E and vitamin E, it is lost weight, the deltoid muscle subcutaneous fat of its subject,
Subcutaneous fat, navel side 3cm subcutaneous fats and anterior superior spine subcutaneous fat are reduced faster under omoplate, and fat-reducing effect becomes apparent from.
5th, girth diameter is measured
The waistline and hip circumference of 10 groups of subjects before and after test-meal are measured, as a result as shown in table 7：
Girth diameter measurement data table before and after the test-meal of table 7
The contrast of A-G groups and J groups can be seen that the l-cn fat-reducing that subject takes embodiment 1-7 offers from table 7
Effervescent tablet 45 days, waistline reduces more than 2.33cm, and hip circumference reduces more than 1.09cm, and the body weight for taking the subject of placebo does not have
There is significant change, the l-cn effervescent tablet for slimming that this explanation embodiment 1-7 is provided can effectively reduce waistline and abdominal circumference size,
With significant fat-reducing effect.
In addition, by the contrast of A-G groups in table 7 and H-I groups as can be seen that the l-cn that embodiment 1-7 is provided subtracts
Fertile effervescent tablet is more by L-carnitine-L-tartrate, Lotus Leafextract, Alisma extract, leucine, xylo-oligosaccharide, optional tea
Phenol, optional haw thorn extract, optional vitamin E, optional Bitter Melon P.E, sour agent, alkaline agent and sweetener coordinated,
It can speed up decomposition fatty in body and be converted into energy, while suppressing absorption of the body to fat and sugar class, reduce external source
The intake of fat and sugar class, so as to reach the purpose that waistline and abdominal circumference are obviously reduced and lost weight.
By the contrast of E-G groups in 7 and A-D groups as can be seen that adding tea in working as the raw material of l-cn effervescent tablet for slimming
After polyphenol, haw thorn extract, Bitter Melon P.E and vitamin E, it is lost weight, and the waistline and abdominal circumference of its subject reduce faster,
Fat-reducing effect becomes apparent from.
Finally it should be noted that：Various embodiments above is merely illustrative of the technical solution of the present invention, rather than its limitations；To the greatest extent
The present invention is described in detail with reference to foregoing embodiments for pipe, it will be understood by those within the art that：Its according to
The technical scheme described in foregoing embodiments can so be modified, or which part or all technical characteristic are entered
Row equivalent substitution；And these modifications or replacement, the essence of appropriate technical solution is departed from various embodiments of the present invention technology
The scope of scheme.
Claims (10)
1. a kind of l-cn effervescent tablet for slimming, it is characterised in that be mainly prepared from by the following raw material according to the mass fraction：
400-500 parts of L-carnitine-L-tartrate, 60-70 parts of Lotus Leafextract, 130-140 parts of Alisma extract, leucine 65-75
Part, 225-245 parts of xylo-oligosaccharide, sour agent 500-600 parts, 200-300 parts of alkaline agent, 1-4 parts of sweetener.
2. l-cn effervescent tablet for slimming according to claim 1, it is characterised in that it is main by according to the mass fraction as
Lower raw material is prepared from：460-470 parts of L-carnitine-L-tartrate, 65-70 parts of Lotus Leafextract, Alisma extract 132-136
Part, 68-72 parts of leucine, 230-240 parts of xylo-oligosaccharide, sour agent 500-600 parts, 200-300 parts of alkaline agent, 2-3 parts of sweetener.
3. l-cn effervescent tablet for slimming according to claim 1 or 2, it is characterised in that also including according to the mass fraction
The following raw material：15-25 parts of Tea Polyphenols, 15-25 parts of Bitter Melon P.E, 3-7 parts of vitamin E, 10-20 parts of haw thorn extract.
4. l-cn effervescent tablet for slimming according to claim 1 or 2, it is characterised in that the sour agent be selected from tartaric acid,
At least one of malic acid, fumaric acid, citric acid or sodium citrate；It is preferred that, the sour agent is malic acid and citric acid
Mixture, and both mass ratioes are 1：(3-4).
5. l-cn effervescent tablet for slimming according to claim 1 or 2, it is characterised in that the alkaline agent be selected from potassium carbonate,
At least one of sodium carbonate, calcium carbonate, saleratus, sodium acid carbonate and calcium bicarbonate；It is preferred that, the alkaline agent is carbonic acid
Sodium.
6. l-cn effervescent tablet for slimming according to claim 1 or 2, it is characterised in that the sweetener is selected from trichlorine
At least one of sucrose, lactose and xylitol；It is preferred that, the sweetener is Sucralose.
7. the preparation method of the l-cn effervescent tablet for slimming according to claim any one of 1-6, it is characterised in that including
Following steps：
(a) by Lotus Leafextract, L-carnitine-L-tartrate, sour agent, optional Tea Polyphenols, optional Bitter Melon P.E, optionally
Haw thorn extract and the mixing of optional vitamin E, the first granule is made；
(b) Alisma extract, xylo-oligosaccharide, alkaline agent and sweetener are well mixed, the second granule is made；
(c) the first granule, the second granule and leucine are well mixed, carry out tabletting, that is, l-cn fat-reducing bubble is made
Rise piece.
8. the preparation method of l-cn effervescent tablet for slimming according to claim 7, it is characterised in that also including step
(s), the step (s) is arranged at before the step (a), and the step (s) is by Lotus Leafextract, L-Carnitine tartrate
It is salt, Alisma extract, xylo-oligosaccharide, sour agent, alkaline agent, sweetener, optional Bitter Melon P.E, optional Tea Polyphenols, optional
Vitamin E, optional haw thorn extract are respectively crushed, and cross 80 mesh sieves.
9. the preparation method of l-cn effervescent tablet for slimming according to claim 7, it is characterised in that first particle
Agent and second granule are formed by drying after wet granulation.
10. the preparation method of l-cn effervescent tablet for slimming according to claim 9, it is characterised in that described first
Granula and the granularity of second granule are 14-18 mesh, preferably 16 mesh.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710594349.6A CN107319242A (en) | 2017-07-20 | 2017-07-20 | L-cn effervescent tablet for slimming and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710594349.6A CN107319242A (en) | 2017-07-20 | 2017-07-20 | L-cn effervescent tablet for slimming and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107319242A true CN107319242A (en) | 2017-11-07 |
Family
ID=60226922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710594349.6A Pending CN107319242A (en) | 2017-07-20 | 2017-07-20 | L-cn effervescent tablet for slimming and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107319242A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109549032A (en) * | 2018-11-22 | 2019-04-02 | 浙江华康药业股份有限公司 | A kind of light body function beverage and preparation method thereof of losing weight |
| CN111990574A (en) * | 2020-09-18 | 2020-11-27 | 内蒙古精晶生物科技有限公司 | L-carnitine nutritional effervescent tablet |
| CN114098088A (en) * | 2021-11-30 | 2022-03-01 | 哈尔滨怡康药业有限公司 | Health preserving composition suitable for regulating body fat of different people and preparation method and application thereof |
| CN116369522A (en) * | 2023-04-10 | 2023-07-04 | 博凯药业有限公司 | Toxin expelling effervescent ball and preparation method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105030978A (en) * | 2015-01-24 | 2015-11-11 | 郑州博凯医药保健品有限公司 | Bio-agent bacterial-inhibiting self-help external-use effervescent tablets |
-
2017
- 2017-07-20 CN CN201710594349.6A patent/CN107319242A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105030978A (en) * | 2015-01-24 | 2015-11-11 | 郑州博凯医药保健品有限公司 | Bio-agent bacterial-inhibiting self-help external-use effervescent tablets |
Non-Patent Citations (2)
| Title |
|---|
| 林宁主编: "《药剂学》", 31 January 2008, 湖北科学技术出版社 * |
| 申请人：郑州博凯医药保健品有限公司: "国食健字G20130277", 《国家食品药品监督管理总局--数据查询》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109549032A (en) * | 2018-11-22 | 2019-04-02 | 浙江华康药业股份有限公司 | A kind of light body function beverage and preparation method thereof of losing weight |
| CN111990574A (en) * | 2020-09-18 | 2020-11-27 | 内蒙古精晶生物科技有限公司 | L-carnitine nutritional effervescent tablet |
| CN114098088A (en) * | 2021-11-30 | 2022-03-01 | 哈尔滨怡康药业有限公司 | Health preserving composition suitable for regulating body fat of different people and preparation method and application thereof |
| CN116369522A (en) * | 2023-04-10 | 2023-07-04 | 博凯药业有限公司 | Toxin expelling effervescent ball and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20040043056A1 (en) | Diet composition comprising raw foods and dietary fibers | |
| CN107183705A (en) | A kind of relax bowel improves the functional food of constipation | |
| CN107319242A (en) | L-cn effervescent tablet for slimming and preparation method thereof | |
| CN106962906A (en) | A kind of dietotherapy slug for the composition of toxin-expelling and face nourishing, containing it and preparation method thereof | |
| WO2006132042A1 (en) | Nutritional supplement powder and fat for food or medicine | |
| CN109549097A (en) | A kind of health caring noodles with functions of reducing sugar and reducing fat | |
| CN102742658B (en) | Goat milk tablet for maintaining beauty and keeping young and preparation method of goat milk tablet | |
| CN104472612A (en) | Natural yeast bread premixed flour for bread capable of coordinating intestines and stomach | |
| CN102687781A (en) | Tartary buckwheat tea effervescent tablets and preparation method thereof | |
| CN106942607A (en) | It is a kind of for relax bowel composition, dietotherapy slug containing it and preparation method thereof | |
| CN103734217A (en) | Dendrobium officinale blood-glucose-reducing and digestion-aiding flour | |
| CN105285381A (en) | Formula feed for cattle and preparation method thereof | |
| CN105580953A (en) | Mulberry tabletting candy production method | |
| CN105520064B (en) | Additive-free whole-grain mung bean nutritional staple food and production method thereof | |
| CN103005277A (en) | Preparation method of high-flavone-content tartary buckwheat tablet | |
| CN102948746A (en) | Milk companion for clearing fire and aiding digestion and preparation method of milk companion | |
| KR100549089B1 (en) | Health functional food for improving bowel function and constipation disease | |
| CN110214902A (en) | A kind of children's correction partial eclipse type selenium-rich complete nourishing powder | |
| CN102048134A (en) | Five-material vegetable nutraceutical and preparation method thereof | |
| CN117837664A (en) | A kind of alcohol-relieving and liver-protecting compressed candy and preparation method thereof | |
| CN100506085C (en) | A brown sugar health product capable of improving the immunity of puerpera | |
| JP2670742B2 (en) | α-amylase inhibitor | |
| CN108095084A (en) | A kind of Zostera marina trepang health food and preparation method thereof | |
| CN104041819B (en) | A kind of ecological fermentation burdock product and preparation method | |
| CN106942561A (en) | A kind of beverage composition for treating dental erosion and preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: No.1302, No.7, Dongqing street, high tech Industrial Development Zone, Zhengzhou City, Henan Province 450001 Applicant after: Bokai Pharmaceutical Co., Ltd Address before: 450000 No. 5 Acacia Street, hi tech Development Zone, Henan, Zhengzhou Applicant before: Zhengzhou Bokai Medicine &. Health-Care Products Co., Ltd. |
|
| CB02 | Change of applicant information | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171107 |
|
| RJ01 | Rejection of invention patent application after publication |